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Abstract
Background
Clinical accuracy of IGRAs remains unclear on patients with immune-mediated inflamma-
tory diseases (IMIDs). Here, we assess the impact of immunosuppressants and IMIDs on
QuantiFERON-TB Gold In-Tube (QFN-G-IT) and T-SPOT.TB accuracy.
Methods
Patients with IMIDs who required latent tuberculosis infection (LTBI) screening were
enrolled and classified into: (i) 50 patients with inflammatory rheumatic diseases, (ii) 50
patients with psoriasis and (iii) 30 patients with Crohn’s disease. A total of 44 healthy individ-
uals without immunosuppression were also included as controls. Tuberculin skin test (TST),
T-SPOT.TB and QFN-G-IT assays were performed. IGRAs were performed following man-
ufacturer’s instructions.
Results
Immunosuppressant’s intake was more frequent on patients with Crohn’s disease and psori-
asis. Positive IGRAs and TST results were reduced in Crohn’s disease patients, whereas
rate of indeterminate T-SPOT.TB results was increased in this group with respect to the
other IMIDs analysed and controls. When IFN-γ response was studied, the levels of this
cytokine after mitogen stimulation were significantly lower in Crohn’s and inflammatory
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rheumatic diseases than in psoriasis. Interestingly, psoriatic patients were the only ones not
receiving corticosteroids. Furthermore, a negative correlation was observed between the
IFN-γ secreted after mitogen stimulation and corticosteroids dose.
Conclusions
IMIDs seem to negatively affect the clinical accuracy of IGRAs, being Crohn’s disease
patients the most affected individuals due to their concomitant drug-profile and impaired
immune response.
Introduction
Patients with immune-mediated inflammatory diseases (IMIDs) have a higher risk of tubercu-
losis (TB) reactivation than common population because of the intake of different immuno-
suppressive therapies and/or their main disease itself. Tumour Necrosis Factor (TNF)-alpha
(α) is a pro-inflammatory key cytokine playing an important role in the immune response
against Mycobacterium tuberculosis. It is crucial for maintaining the granuloma formation and
thus containing the infection caused by the bacilli. Therefore, ruling out latent tuberculosis
infection (LTBI) and active TB is mandatory prior anti-TNF-αprescription as well as during
treatment [1, 2].
Interferon (IFN)-gamma (γ) Release Assays (IGRAs) used for LTBI diagnosis detect the
IFN-γ cytokine secreted by sensitized T-cells after stimulating with specific M. tuberculosis
antigens [3]. There are two assay formats: QuantiFERON technology (QFN; Qiagen, Du¨ssel-
dorf, Germany) and T-SPOT.TB (Oxford Immunotec, Abingdon, UK), both approved by
the U.S. Food and Drug Administration (FDA) and the CE (for their use in Europe). Cur-
rently, these assays are useful tools for diagnosing LTBI because they are not affected by
BCG-vaccination and/or non-tuberculous mycobacteria (NTM) sensitization [4–6]. In addi-
tion, IGRAs’ methodology contain a positive control [stimulation with phytohaemagglutinin
(PHA) as a mitogen] which detects the presence of anergy. This control is very useful in
individuals with a weak immune response due to the intake of several immunosuppressant
therapies or the presence of a certain underlying disease. Therefore, the inclusion of this
mitogen could be particularly useful in patients with IMIDs [7]. However, clinical perfor-
mance of IGRAs remains still unclear in these kind of patients. Currently, available data
on the usefulness of IGRAs in patients with IMIDs is diverse due to the population heteroge-
neity and the variety of immunosuppressant drug-regimens analysed [8, 9]. Therefore,
research in this direction should be further considered. In the present study, we have investi-
gated the impact of different immunosuppressant therapies and IMIDs on QFN-TB Gold
In-Tube (QFN-G-IT) and T-SPOT.TB assays.
Materials and methods
Study participants
A total of 130 patients and 44 healthy controls were enrolled in the study. Samples were col-
lected from Rheumatology, Dermatology, Gastroenterology and Preventive Medicine Depart-
ments located in Hospital Universitari Germans Trias I Pujol (Badalona, Spain). The study
was approved by the Ethics Committee of the Hospital Germans Trias i Pujol. All experiments
were performed in accordance with the relevant guidelines and regulations. All the patients
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enrolled in this study gave a written informed consent. A total of 11 mL of blood was collected
from each patient.
Tuberculin skin testing
Tuberculin skin test (TST) was administered using the Mantoux method and interpreted
according to Spanish Society of Pneumology Guidelines by qualified members of the research
team. TST was considered positive when the induration was higher than 5mm [10]. In order
to avoid TST booster effect over IGRAs, TST and blood extraction for T-SPOT.TB and
QFN-G-IT were performed simultaneously [11]. The study was double-blinded: TST was
interpreted without knowing IGRAs’ results, and at the same time, researchers did not know
the clinical data and the TST result prior to performing the tests.
IFN-γ release assays and results interpretation
T-SPOT.TB and QFN-G-IT assays were performed and interpreted following manufacturer’s
instructions. For T-SPOT.TB assay a total of 8 mL of blood were collected. Spot-forming cells
(SFC) were counted using an automated AID ELISPOT reader (AID Systems, Strasberg, Ger-
many). The results were also checked and validated by naked eye. The assay was considered
positive when the test wells contained at least six SFC more than the negative control, and this
number was at least twice the number of the negative control well. The result was considered
indeterminate if both antigen-stimulated wells were negative and if the number of SFC in the
positive control was less than <20; and/or if SFC counted in the negative control well was>10.
For QFN-G-IT a total of 3 mL of blood was collected into three tubes (negative, TB-Antigen
and positive). For this assay, a result was considered positive when the IU/mL of IFN-γ
secreted was0.35 for the TB-Antigen tube. A result was scored as indeterminate when the
TB-antigen tube was negative and the mitogen tube presented less than 0.5 IU/mL of IFN-γ
secreted (positive control); and/or if the negative control tube was higher than 8.0 UI/mL.
Measurements >10IU/mL in QFN-G-IT were set as 10IU/mL according to the upper limit of
the assay and manufacturer’s instructions.
Statistical analysis
Differences on the assay results based on the clinical therapeutic profile and the underlying dis-
ease was assessed and analysed using the Chi-square test. Association between the IFN-γ
response and corticosteroid doses was assessed using Spearman correlation coefficient. The
amount of IFN-γ secreted was investigated as well in each group. In this case, comparisons
among the three study groups were performed using the Kruskall-Wallis test. In addition,
Mann-Whitney U test was applied for pairwise comparisons. Differences were considered
statistical significant when a p-value was<0.05. All analyses were performed using the SPSS sta-
tistical software for windows (SPSS version 15.0; SPSS Inc, Chicago, IL, USA). Graphical repre-
sentation is based on GraphPad Prism version 4 (GraphPad Software, Inc, San Diego, CA).
Results
Patient characteristics and concomitant drug-profile when IGRAs where
performed
We enrolled a total of 130 IMID patients who required LTBI screening before starting systemic
immunosuppressive treatment or during its sustained use. Patients were screened in the course
of their routine examinations and had no known risk of TB exposure. They were classified into
three groups: (i) 50 patients with inflammatory rheumatic diseases, (ii) 50 patients with
IGRAs’ accuracy on immune-mediated inflammatory diseases
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moderate-to-severe psoriasis and (iii) 30 patients with Crohn’s disease. A total of 44 healthy
individuals without immunosuppression were also included as controls. They were healthcare
workers with no risk of TB exposure and recruited in the course of routine examinations.
Patient characteristics and their specific underlying disease regarding the study group is
detailed in Table 1. Briefly, the proportion of patients on immunosuppressants (DMARDs or
biologics) when IGRAs were performed varied significantly regarding the underlying disease
(p = 0.016). It was higher in patients with Crohn’s disease (90%; 27/30) and psoriasis (82%;
41/50) with respect to inflammatory rheumatic patients (64%; 32/50). The 75% (24/32) of
rheumatic patients were receiving one DMARD and the 25% (8/32) were taking two. The
46.3% (19/41) of patients with psoriasis were receiving classic systemic treatment (cyclosporine
or methotrexate) and the 53.7% (22/41) were already taking biologicals (infliximab, etanercept,
adalimumab or ustekinumab). The 81.5% (22/27), 11.1% (3/27) and 7.4% (2/27) of Crohn’s
disease patients were treated with azathioprine, methotrexate and biologicals (infliximab)
respectively. Corticosteroid therapy was frequent in patients with inflammatory rheumatic dis-
eases (40%; 20/50) and Crohn’s disease (33.3%; 10/30), while it was absent in psoriatic patients
(Table 1).
IGRAs’ clinical accuracy regarding IMID type
Overall, the percentage of positive results by either of the two IGRAs were 22.7% (10/44), 22%
(11/50), 24% (12/50), and 13.3% (4/30) in healthy controls, patients with psoriasis, rheumatic
Table 1. Patients’ characteristics, final diagnosis and present treatment regarding IMID type.
VARIABLE Psoriasis n = 50
(%)
Inflammatory rheumatic diseases n = 50
(%)
Crohn’s disease n = 30
(%)
Healthy controls n = 44
(%)
Mean age (years) ± SD 45.52±13.05 49.58±13.11 38.16±13.94 36.21±7.22
Gender
Male 37 (74) 17 (34) 16 (53.3) 10 (22.7)
Female 13 (26) 33 (66) 14 (46.7) 34 (77.3)
Diagnosis
Moderate-to-severe
psoriasis
50 (100) 0 (0) 0 (0) N/A
Rheumatoid arthritis 0 (0) 16 (32) 0 (0) N/A
Ankylosing spondylitis 0 (0) 12 (24) 0 (0) N/A
Psoriatic arthritis 0 (0) 9 (18) 0 (0) N/A
Crohn’s disease 0 (0) 0 (0) 30 (100) N/A
Other* 0 (0) 13 (26) 0 (0) N/A
Present corticoids
Yes 0 (0) 20 (40) 10 (33.3) N/A
No 50 (100) 30 (60) 20 (66.7) N/A
Present DMARDs
Yes 19 (38) 32 (64) 25 (83.3) N/A
No 31 (62) 18 (36) 5 (16.7) N/A
Present biologics
Yes 22 (44) 0 (0) 2 (6.7) N/A
No 28 (56) 50 (100) 28 (93.3) N/A
SD: standard deviation
*Systemic lupus erythematosus (n = 4), SAPHO syndrome (n = 4), seronegativepolyarthritis (n = 3), undifferenciated spondiloarthropaty (n = 1) and
spondylitis associated with inflammatory bowel disease (n = 1).
https://doi.org/10.1371/journal.pone.0189202.t001
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inflammatory diseases and Crohn’s disease respectively. In addition, a considerable percentage
of IMIDs patients with negative TST (12.7%; 14/110) were positive for one of the two IGRAs.
The percentage of positive results in patients with psoriasis, inflammatory arthritis, Crohn’s
disease and healthy controls is represented for the three assays in Fig 1A–1C. The rate of posi-
tive results obtained by T-SPOT.TB, QFN-G-IT and TST was higher in patients with inflam-
matory rheumatic diseases, psoriasis and healthy controls with respect to Crohn’s disease
individuals (differences not significant). Indeterminate results were obtained by T-SPOT.TB
and QFN-G-IT in a 10% [13/130; 10 cases due to insufficient mitogen (PHA) response and 3
due to high response in negative control) and a 5.4% (7/130; all due to insufficient PHA
response)] of the cases respectively. All indeterminate results due to insufficient PHA response
corresponded with negative TSTs. The percentage of indeterminate results observed by
T-SPOT.TB in patients with Crohn’s disease diagnosis was significantly higher than in rheu-
matic patients, those diagnosed with psoriasis and healthy controls (p = 0.003, p = 0.009 and
p = 0.002 respectively). Seven out of the eight Crohn’s disease patients with indeterminate
results corresponded to individuals receiving azathioprine. Furthermore, three of them were
receiving corticosteroid therapy. Concordances between both IGRAs were good when they
were analysed globally (κ = 0.817) and based on the study groups (κ = 0.849 for rheumatic
inflammatory diseases, κ = 0.799 for psoriasis and κ = 0.773 for Crohn’s disease). By means of
an univariate analysis, no significant differences were observed between the results obtained
by either IGRAs or TST with biologics, corticoids or DMARDs received (Table 2).
Impact of immunosuppressive therapies on the IFN-γ response
The SFC and the IFN-γ response in T-SPOT.TB and QFN-G-IT was assessed in those positive
responders after specific antigen stimulation, and evaluated regarding the underlying inflam-
matory disease. No significant differences were found between study groups (p = 0.101 and
p = 0.574 respectively, data analysed with Kruskall-Wallis test). In order to further study the
impact of different IMIDs on clinical assay accuracy, the amount of IFN-γ released after PHA
Fig 1. Percentage of positive, negative and indeterminate results. Percentages are represented for (a) T-SPOT.
TB, (b) QFN-G-IT and (c) TST in patients with psoriasis (black bars), inflammatory arthritis diseases (grey bars),
Crohn disease (white bars) and healthy controls (spot bars). Inflam. Arth: Inflammatory arthritis; QFN-G-IT:
QuantiFERON-TB Gold In-Tube; TST: Tuberculin skin test.
https://doi.org/10.1371/journal.pone.0189202.g001
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stimulation in QFN-G-IT was analysed in the overall population. Interestingly, in Crohn’s and
rheumatic disease patients, the IFN-γ cytokine secreted by sensitized T cells after PHA stimu-
lation was significantly lower with respect to psoriasis and healthy controls (Fig 2; p<0.0001
for all comparisons). Psoriatic patients were the only ones not receiving corticosteroids. A cor-
relation between the IFN-γ secreted after mitogen stimulation and dose (mg/day) of cortico-
steroid administered was performed. There was a negative moderate correlation (Fig 3;
Spearman’s Rho = -0.489; p = 0.007).
Discussion
Investigations on IGRAs in high risk individuals are still limited, and it is necessary to compare
and study how IMIDs with different immunosuppressive regimen can affect in vitro assays’
accuracy. Our research group have previously assessed in two independent studies the useful-
ness of IGRAs on patients with arthritic [12] and psoriatic [13] diseases, indicating that IGRAs
seem to be helpful for LTBI diagnosis in such populations. In both studies we found that posi-
tive results for T-SPOT.TB/QFN-G-IT and the amount of T-cell response were not affected by
clinical therapeutic profile. However, the effect of therapy on IFN-γ detection may depend on
IMID type and its concomitant therapy. Here, we compare three different types of IMIDs (pso-
riasis, rheumatic inflammatory disease and Crohn’s disease) from patients enrolled in the
same study setting. Furthermore, the study shows that accuracy of T-SPOT.TB and QFN-G-IT
is differentially affected regarding the IMID type and its concomitant drug-treatment. The
Table 2. Association of the immunosuppressant treatment received with TST, QFN-G-IT and T-SPOT.TB positivity by means of univariate
analysis.
Risk Factors TST; n (%) QFN-G-IT; n (%) T-SPOT.TB; n (%)
Positive Negative p-value Positive Negative p-value Positive Negative p-value
Totala 17 110 NA 22 101 NA 22 95 NA
Mean age (years) ± SDb 52.53
±12.50
44.42
±14.47
0.031 57.19
±10.68
43.62
±13.81
<0.0001 56.76
±13.16
43.71
±12.64
<0.0001
Gender
Male 11 (64.7) 56 (50.9) 0.289 18 (81.8) 51 (50.5) 0.007 17 (77.3) 46 (48.4) 0.014
Female 6 (35.3) 54 (49.1) 4 (18.2) 50 (49.5) 5 (22.7) 49 (51.6)
Present immunosuppressants (DMARDs
or biologics)
Yes 12 (70.6) 85 (77.3) 0.548c 17 (77.3) 78 (77.2) 0.996 15 (68.2) 76 (80.0) 0.259c
No 5 (29.4) 25 (22.7) 5 (22.7) 23 (22.8) 7 (31.8) 19 (20.0)
Present DMARDs
Yes 9 (52.9) 66 (60.0) 0.582 11 (50.0) 60 (59.4) 0.418 11 (50.0) 58 (61.1) 0.342
No 8 (47.1) 44 (40.0) 11 (50.0) 41 (40.6) 11 (50.0) 37 (38.9)
Present biologics
Yes 3 (17.6) 19 (17.3) 1.000c 6 (27.3) 18 (17.8) 0.373c 4 (18.2) 18 (18.9) 1.000c
No 14 (82.4) 91 (82.7) 16 (72.7) 83 (82.2) 18 (81.8) 77 (81.1)
Present corticoids
Yes 4 (23.5) 26(23.6) 1.000c 5 (22.7) 22(21.8) 0.923 5 (22.7) 22(23.2) 0.966
No 13 (76.5) 84(76.4) 17 (77.3) 79(78.2) 17 (77.3) 73(76.8)
NA: non-applicable; SD: standard deviation. P vàlues less than 0.05 were considered significant.
aExcluding indeterminate QFN-G-IT and/or T-SPOT.TB results.
bSignificance on age was calculated using Student’s T test.
cSignificance was calculated using Fisher’s Exact test, since the 25% of expected frequency were less than 5.
https://doi.org/10.1371/journal.pone.0189202.t002
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overall number of positive results obtained here by TST and IGRAs were reduced in patients
suffering Crohn’s disease with respect to those with rheumatic disorders or psoriasis. Similarly,
Ramos JM. et al. conducted a study using QFN-G-IT and TST assays in our region, observing
that positive results were negatively affected by immunosuppressive therapy in patients with
inflammatory bowel diseases. However indeterminate results obtained were low, therefore, no
associations were established [14]. Low rates of positive IGRAs results on patients with inflam-
matory bowel diseases under azathioprine have been previously mentioned by others when
they are compared with bowel disease patients under other drug-regimens or without immu-
nosuppressive treatment [15]. Interestingly, the majority of Crohn’s disease patients included
in our study were under this immunosuppressant drug.
Generally, the frequency of QFN-G-IT indeterminate results has been linked to patients
with chronic inflammatory diseases under glucocorticoid use [8, 16–19]. In line with this, our
results reveal that number of IGRA’s indeterminate results is even higher in Crohn’s disease
patients under azathioprine. Moreover, the induced-mitogen response was reduced in this
group and also in patients with rheumatic diseases with respect to those patients with psoriasis.
Intriguingly, the 33.3% of Crohn’s disease patients and the 40% of individuals with rheumatic
diseases were on corticosteroid therapy. Be´lard E. et al. found a significant negative effect of
prednisolone on IFN-γ response, indeterminate QFN-G-IT results and positive TST results.
They also compared the IFN-γ response after mitogen stimulation in several therapy groups,
and found that it was reduced in patients with corticosteroid treatment when they were com-
pared with those not receiving treatment or other therapy without corticosteroid [16]. In order
to study whether the immune response was influenced by corticosteroid treatment, we
Fig 2. IFN-γ released after mitogen (PHA) overnight stimulation (Mit-Nil) in QFN-G-IT based on the
study group of patients analyzed. The median cytokine levels from each group is represented by a line.
Mann-Whitney U analysis was applied for pairwise comparisons. Measurements >10IU/mL were set as 10IU/
mL according to the upper limit of the assay and manufacturer’s instructions. Only significant differences were
indicated in the figure. It was not possible to assess the IFN-γ response after PHA stimulation in T-SPOT.TB
assay due to saturation in the control well (>250 spot-forming cells). Inflam. Arth: Inflammatory arthritis; PHA:
Phytohaemagglutinin; QFN-G-IT: QuantiFERON-TB Gold In-Tube.
https://doi.org/10.1371/journal.pone.0189202.g002
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correlated both IFN-γ released upon PHA stimulation with dose (mg/day) of corticosteroid
administered, observing that this response diminished when the dose of corticosteroids aug-
mented. In addition, a recent study has assessed the impact of corticosteroids on QFN-G-IT
suggesting that they can significantly impair IGRAs accuracy [20]. Consequently, we have to
pay attention when ruling out LTBI in this specific group of patients due to false-negative
TST/IGRAs and low IFN-γ cytokine secretion that can lead to indeterminate results. In this
direction, some studies report that a long in vitro stimulation of T cells (6–9 days) can detect a
memory response and may be can be used to identify LTBI individuals who resulted to have
negative IGRAs. More studies need to confirm these data, however, this could be a useful tool
on patients under immunosuppressive treatment who have high risk of developing TB [21–
23].
Taken together, here we describe how IMIDs can negatively affect the accuracy of IGRAs,
being Crohn’s disease patients the most affected individuals due to their concomitant immu-
nosuppressant drug-profile and impaired immune response. Therefore, in the absence of a
gold standard, it seems prudent to diagnose LTBI using both the TST and IGRAs with the aim
of detecting all possible cases in patients with IMIDs [24, 25], giving special attention to those
with a poor accuracy of IGRAs and/or TST such as Crohn’s disease. In addition, the use of
TST in psoriasis has to be taken with caution. Previous observations indicate that psoriasis can
produce a TST hyper-reactivity due to a skin over-reaction to a broad range of antigens. There-
fore, it is necessary to re-evaluate a positive TST reaction in these patients because in most situ-
ations it could lead to a LTBI over-diagnosis [26].
Fig 3. Correlation between the IFN-γ secreted after mitogen (PHA) stimulation and dose (mg/day) of
corticosteroid administered. Association between the IFN-γ response on QFN-G-IT and corticosteroid
doses was assessed using Spearman correlation coefficient. Measurements >10IU/mL were set as 10IU/mL
according to the upper limit of the assay and manufacturer’s instructions. It was not possible to assess the
IFN-γ response after PHA stimulation in T-SPOT.TB assay due to saturation in the control well (>250 spot-
forming cells). PHA: Phytohaemagglutinin; QFN-G-IT: QuantiFERON-TB Gold In-Tube; SR: Spearman’s
Rho.
https://doi.org/10.1371/journal.pone.0189202.g003
IGRAs’ accuracy on immune-mediated inflammatory diseases
PLOS ONE | https://doi.org/10.1371/journal.pone.0189202 December 7, 2017 8 / 11
It is still necessary to make efforts for an accurate LTBI diagnosis in IMIDs’ patients. In this
direction, a new improved IGRA version called QFN-Plus has appeared. This assay includes
new designed peptides form M. tuberculosis capable to induce specific CD4 and CD8 T cells.
Data about its better accuracy over classical IGRAs is still limited, and there are not yet results
evidencing a better sensitivity and specificity in this population [27–30]. Another encouraging
approach seems to be the study of other cytokines different from IFN-γ. In the last years, the
cytokine called IFN-γ-induced protein-10 (IP-10) has emerged as a promising biomarker for
LTBI diagnosis that enables to rise sensitivity in conjunction with IFN-γ [31–34]. We should
focus investigations on this direction: improving LTBI diagnostics on high-risk individuals,
increasing sensitivity and minimizing false-negative and indeterminate results.
In conclusion, clinical accuracy of IGRAs for LTBI diagnosis seems to be differentially
affected by the IMID type. Particularly, Crohn’s disease and/or its concomitant immunosup-
pressive drug-profile could negatively affect accuracy of T-SPOT.TB and QFN-G-IT when
compared with psoriasis orinflammatory rheumatic diseases. Therefore, it is important to be
prudent when diagnosing LTBI in this kind of patients due to the high frequency of indetermi-
nate results and an attenuated IFN-γ response.
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